<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852513</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 12-1812</org_study_id>
    <nct_id>NCT01852513</nct_id>
  </id_info>
  <brief_title>Allergic Rhinitis Changes the Sinus Microbiome</brief_title>
  <official_title>Allergic Rhinitis Changes the Sinus Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that treatment with QNASL will reduce nasal mucosal&#xD;
      inflammation induced by the allergy season and prevent the changes in the microbiome caused&#xD;
      by the allergy season.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Nasal Symptom Score (TNSS)</measure>
    <time_frame>Two weeks following initiation of treatment</time_frame>
    <description>The Total Nasal Symptom Score (TNSS) is the sum of scores for each of nasal congestion, sneezing, nasal itching, and rhinorrhea using a four point scale (0-3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. TNSS is calculated by adding the score for each of the symptoms to a total out of 12. TNSS was assessed daily and summed over 14 days; thus, the total score ranges from 0 to 168, with higher scores indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in RQLQ Score From Baseline to Two Weeks</measure>
    <time_frame>Two weeks following initiation of treatment</time_frame>
    <description>The Rhinoconjunctivitis Quality Of Life Questionnaire (RQLQ) is a self-administered disease-specific health-related quality of life instrument that measures the functional impairments that are most troublesome to adult patients as a result of their seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. There are 28 items each asking about symptoms during the previous week. Seven domains of activity limitation are included: activities (3 &quot;patient-specific&quot;) limitation, sleep problems (3 items), nose symptoms (4 items), eye symptoms (4 items), non-nose/eye symptoms (7 items), practical problems (3 items) and emotional function (4 items)). Each item is reported using a 7-point scale (0 = not impaired at all, 6 = severely impaired), and a total score is calculated by averaging over all items (range 0-7). Higher scores reflect lower quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percent Eosinophils From Baseline to Two Weeks</measure>
    <time_frame>Two weeks following initiation of treatment</time_frame>
    <description>The percentage of nasal eosinophils recovered from nasal lavage was assessed at baseline and after two weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>QNASL nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QNASL</intervention_name>
    <arm_group_label>QNASL nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females between 18 and 55 years of age.&#xD;
&#xD;
          2. Two year history of seasonal allergic rhinitis.&#xD;
&#xD;
          3. Positive skin test to grass and/or tree antigen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.&#xD;
&#xD;
          2. Pregnant or lactating women.&#xD;
&#xD;
          3. Subjects treated with systemic steroids during the previous 30 days.&#xD;
&#xD;
          4. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom&#xD;
             or Opticrom during the previous 30 days.&#xD;
&#xD;
          5. Subjects treated with oral antihistamine/decongestants during the previous seven days.&#xD;
&#xD;
          6. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants&#xD;
             during the previous 3 days.&#xD;
&#xD;
          7. Subjects treated with immunotherapy and are escalating their dose.&#xD;
&#xD;
          8. Subjects on chronic anti-asthma medications.&#xD;
&#xD;
          9. Subjects with polyps in the nose or a significantly displaced septum.&#xD;
&#xD;
         10. Upper respiratory infection within 14 days prior to study start.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayant Pinto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <results_first_submitted>October 5, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2020</results_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>QNASL Nasal Spray</title>
          <description>QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
QNASL</description>
        </group>
        <group group_id="P2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
Placebo nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QNASL Nasal Spray</title>
          <description>QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
QNASL</description>
        </group>
        <group group_id="B2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
Placebo nasal spray</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Nasal Symptom Score (TNSS)</title>
        <description>The Total Nasal Symptom Score (TNSS) is the sum of scores for each of nasal congestion, sneezing, nasal itching, and rhinorrhea using a four point scale (0-3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. TNSS is calculated by adding the score for each of the symptoms to a total out of 12. TNSS was assessed daily and summed over 14 days; thus, the total score ranges from 0 to 168, with higher scores indicating a worse outcome.</description>
        <time_frame>Two weeks following initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>QNASL Nasal Spray</title>
            <description>QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
QNASL</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
Placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Total Nasal Symptom Score (TNSS)</title>
          <description>The Total Nasal Symptom Score (TNSS) is the sum of scores for each of nasal congestion, sneezing, nasal itching, and rhinorrhea using a four point scale (0-3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. TNSS is calculated by adding the score for each of the symptoms to a total out of 12. TNSS was assessed daily and summed over 14 days; thus, the total score ranges from 0 to 168, with higher scores indicating a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="43.2"/>
                    <measurement group_id="O2" value="78.0" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.391</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in RQLQ Score From Baseline to Two Weeks</title>
        <description>The Rhinoconjunctivitis Quality Of Life Questionnaire (RQLQ) is a self-administered disease-specific health-related quality of life instrument that measures the functional impairments that are most troublesome to adult patients as a result of their seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. There are 28 items each asking about symptoms during the previous week. Seven domains of activity limitation are included: activities (3 &quot;patient-specific&quot;) limitation, sleep problems (3 items), nose symptoms (4 items), eye symptoms (4 items), non-nose/eye symptoms (7 items), practical problems (3 items) and emotional function (4 items)). Each item is reported using a 7-point scale (0 = not impaired at all, 6 = severely impaired), and a total score is calculated by averaging over all items (range 0-7). Higher scores reflect lower quality of life.</description>
        <time_frame>Two weeks following initiation of treatment</time_frame>
        <population>Those analyzed included all participants with data for this measure at baseline and two weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>QNASL Nasal Spray</title>
            <description>QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
QNASL</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
Placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in RQLQ Score From Baseline to Two Weeks</title>
          <description>The Rhinoconjunctivitis Quality Of Life Questionnaire (RQLQ) is a self-administered disease-specific health-related quality of life instrument that measures the functional impairments that are most troublesome to adult patients as a result of their seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. There are 28 items each asking about symptoms during the previous week. Seven domains of activity limitation are included: activities (3 &quot;patient-specific&quot;) limitation, sleep problems (3 items), nose symptoms (4 items), eye symptoms (4 items), non-nose/eye symptoms (7 items), practical problems (3 items) and emotional function (4 items)). Each item is reported using a 7-point scale (0 = not impaired at all, 6 = severely impaired), and a total score is calculated by averaging over all items (range 0-7). Higher scores reflect lower quality of life.</description>
          <population>Those analyzed included all participants with data for this measure at baseline and two weeks.</population>
          <units>Change in scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.1"/>
                    <measurement group_id="O2" value="1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.789</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent Eosinophils From Baseline to Two Weeks</title>
        <description>The percentage of nasal eosinophils recovered from nasal lavage was assessed at baseline and after two weeks of treatment.</description>
        <time_frame>Two weeks following initiation of treatment</time_frame>
        <population>Those analyzed included all participants with data for this measure at baseline and two weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>QNASL Nasal Spray</title>
            <description>QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
QNASL</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
Placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Eosinophils From Baseline to Two Weeks</title>
          <description>The percentage of nasal eosinophils recovered from nasal lavage was assessed at baseline and after two weeks of treatment.</description>
          <population>Those analyzed included all participants with data for this measure at baseline and two weeks.</population>
          <units>Change in percentage of eosinophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.5"/>
                    <measurement group_id="O2" value="2.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.778</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two weeks following initiation of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>QNASL Nasal Spray</title>
          <description>QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
QNASL</description>
        </group>
        <group group_id="E2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment&#xD;
Placebo nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jayant Pinto, PI</name_or_title>
      <organization>The University of Chicago</organization>
      <phone>773-702-6727</phone>
      <email>jpinto@surgery.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

